Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Three-Arm, Double-Blind, Single Dose Study to Compare the Safety and Pharmacokinetics of the Potential Biosimilar NeuCeptin with Trastuzumab in Healthy Male Volunteers

Trial Profile

A Phase 1, Randomized, Three-Arm, Double-Blind, Single Dose Study to Compare the Safety and Pharmacokinetics of the Potential Biosimilar NeuCeptin with Trastuzumab in Healthy Male Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Oct 2018

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer; Gastric cancer
  • Focus First in man; Pharmacokinetics
  • Sponsors NeuClone
  • Most Recent Events

    • 23 Oct 2018 According to a NeuClone media release, first patient has been dosed in this study.
    • 23 Oct 2018 According to a NeuClone media release, this study is being conducted under the Australian Clinical Trial Notification (CTN) scheme.
    • 23 Oct 2018 Status changed from not yet recruiting to recruiting, according to a NeuClone media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top